L
Lore Decoster
Researcher at Vrije Universiteit Brussel
Publications - 85
Citations - 1894
Lore Decoster is an academic researcher from Vrije Universiteit Brussel. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 19, co-authored 70 publications receiving 1321 citations.
Papers
More filters
Journal ArticleDOI
Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations
Lore Decoster,K. Van Puyvelde,Supriya G. Mohile,Ulrich Wedding,Umberto Basso,Giuseppe Colloca,Siri Rostoft,Janine Overcash,Hans Wildiers,Christopher Steer,Gretchen Kimmick,Ravindran Kanesvaran,Andrea Luciani,Catherine Terret,Arti Hurria,Cindy Kenis,Riccardo A. Audisio,Martine Extermann +17 more
TL;DR: Screening tools do not replace GA but are recommended in a busy practice in order to identify those patients in need of full GA and guided multidisciplinary interventions.
Journal ArticleDOI
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.
Jeroen de Filette,Joeri J Pen,Lore Decoster,Thomas Vissers,Bert Bravenboer,Bart Van Der Auwera,Frans Gorus,Bart O. Roep,Bart O. Roep,Sandrine Aspeslagh,Bart Neyns,Brigitte Velkeniers,Aan V. Kharagjitsingh +12 more
TL;DR: ICI-related diabetes mellitus is a rare but often life-threatening metabolic urgency of which health-care professionals and patients should be aware.
Journal ArticleDOI
Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients.
Helen Boyle,Shabbir M.H. Alibhai,Lore Decoster,Eleni Efstathiou,Karim Fizazi,Nicolas Mottet,Stéphane Oudard,H. Payne,M. Prentice,Martine Puts,Matti Aapro,Jean-Pierre Droz +11 more
TL;DR: The 2019 SIOG Task Force recommendations are that men aged 75 years and older with prostate cancer should be managed according to their individual health status, and not according to age.
Journal ArticleDOI
Functional decline in older patients with cancer receiving chemotherapy: A multicenter prospective study
Cindy Kenis,Lore Decoster,Julie Bastin,Hannelore Bode,Katrien Van Puyvelde,Jacques De Greve,Godelieve Conings,Katleen Fagard,Johan Flamaing,Koen Milisen,Jean-Pierre Lobelle,Hans Wildiers +11 more
TL;DR: Functional decline occurs in about a third of older patients with cancer receiving chemotherapy and is associated with GA components, and strongly predicts survival, the most prominent for ADL.
Journal ArticleDOI
Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib
Amir Noeparast,Erik Teugels,Philippe Giron,Gil Verschelden,Sylvia De Brakeleer,Lore Decoster,Jacques De Greve +6 more
TL;DR: It is demonstrated that both types of non-V600 BRAF mutations can be sensitive to clinically relevant doses of Dabrafenib and Trametinib in HEK293T cells, in lung epithelial cellular model (BEAS-2B) and in human cancer cell lines harboring non-BRAF mutations.